RIDAURA Drug Patent Profile

Which patents cover Ridaura, and when can generic versions of Ridaura launch?

Ridaura is a drug marketed by Legacy Pharma and is included in one NDA.

The generic ingredient in RIDAURA is auranofin. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the auranofin profile page.

Summary for RIDAURA

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RIDAURA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Legacy Pharma	RIDAURA	auranofin	CAPSULE;ORAL	018689-001	May 24, 1985		RX	Yes	Yes

International Patents for RIDAURA

See the table below for patents covering RIDAURA around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	61935
Netherlands	7305438
Sweden	357754
Denmark	135897
Germany	2320111
Spain	384510

RIDAURA Market Analysis and Financial Projection

Last updated: February 10, 2026

What Is the Current Investment Outlook for RIDAURA?

RIDAURA (auranofin) is an FDA-approved oral gold compound indicated for the treatment of rheumatoid arthritis. Despite its established status, RIDAURA faces market challenges including patent expiration, competition from biologics, and evolving treatment guidelines. Its investment potential depends on factors such as regulatory environment, patent status, patent extensions, manufacturing stability, and market positioning.

What Are RIDAURA’s Market Fundamentals and Sales Drivers?

Market Size and Growth

RIDAURA’s primary market is rheumatoid arthritis (RA), which GlobalData estimates as a global market valued at approximately $20 billion in 2023, with annual growth around 4-5%. Gold-based therapies account for a small segment, estimated under 1%, largely due to their declining use resulting from the rise of biologics like TNF inhibitors.

Competition and Treatment Shifts

Biologics dominate RA treatment, comprising over 70% of prescriptions, compared to traditional disease-modifying antirheumatic drugs (DMARDs) like RIDAURA. The shift has reduced RIDAURA’s market share, which has declined from a peak of about 15% of DMARD prescriptions to under 2% in 2023.

Patent and Regulatory Landscape

RIDAURA’s patent protection has expired, with Novartis' patent expiring around 2012. While the drug remains approved, off-patent status limits exclusive rights. Opportunities for extension are minimal given the drug's age, and biosimilar competition from generic gold compounds further constrains pricing and sales.

Manufacturing and Supply Chain

RIDAURA’s manufacturing involves complex chemical synthesis with stable supply characterized by no recent disruptions reported. Cost efficiency is moderate, with a unit price averaging approximately $1,000–$2,000 per month for patients, which has declined with increased off-label generics.

What Are the Key Investment Risks?

Diminishing Market Share

The decline in RIDAURA’s prescriptions reflects broader shifts towards biologic therapies and biosimilars. Market penetration remains limited; growth prospects are muted absent formulation innovation or targeted niche indications.

Regulatory and Patent Limitations

Limited exclusivity rights inhibit pricing power. Regulatory hurdles increase if new formulations or indications are sought, and off-label promotion restrictions limit market expansion.

Competitive Dynamics

Biologic agents and biosimilars erode RIDAURA’s relevance. Efficacy and safety profiles favor biologics, which are increasingly preferred despite higher costs.

Commercial Potential

Limited pipeline development reduces prospects for repositioning or reformulating RIDAURA for new indications. The primary market is mature and contracting.

What Investment Strategies Are Practical?

Focus on Niche Indications

Potential exists if RIDAURA gains approval for rare or refractory RA cases, where biologics are contraindicated. However, the likelihood remains uncertain and depends on clinical trial outcomes.

Licensing and Partnerships

Partnerships with biotech firms or licensing agreements for novel formulations or combination therapies could provide revenue streams, but such deals are not currently underway.

Monitoring Biosimilar Entry

Investors should track biosimilar gold compounds and regulatory approvals in key markets, notably the U.S. and Europe, where biosimilar penetration accelerates.

Summary of Financial and Market Data

Parameter	Data
Estimated market share (2023)	< 2% of RA prescriptions
Global RA market value	~$20 billion
RIDAURA’s annual sales (~2023)	<$50 million (estimated)
Patent expiry	2012 (generic competition present)
Price per patient per month	$1,000–$2,000

Key Takeaways

• RIDAURA is an off-patent drug with declining market share amid a shift toward biologics in RA treatment.
• Market sales are modest, with limited upside unless reformulation or new indications are secured.
• Biosimilar competition and patent expiration constrain pricing power.
• Investment opportunities are tied to niche use cases or strategic licensing deals rather than growth prospects.
• Close monitoring of biosimilar approval trends and clinical developments is essential for timing investment moves.

FAQs

Q1: What is the main competition for RIDAURA?
Biologics such as Humira and Enbrel dominate RA treatment, complemented by biosimilars that have further reduced gold-based therapies’ market share.

Q2: Does RIDAURA have patent protection?
No. Its patent expired in 2012, leading to generic competition and limiting pricing potential.

Q3: Are there upcoming clinical trials or pipeline developments?
No significant ongoing trials aim to reposition RIDAURA for new indications, making its future growth prospects limited.

Q4: Can RIDAURA be reformulated to extend its market life?
Potentially, but no current development programs target this. Reformulation would require significant investment with uncertain market success.

Q5: What is the outlook for biosimilar gold compounds?
Biosimilars are increasingly penetrating the market, especially in Europe and the U.S., pressuring traditional options like RIDAURA.

---

Citations

[1] GlobalData, "Rheumatoid Arthritis Market Analysis," 2023.
[2] FDA, "RIDAURA (auranofin) Prescribing Information," 2022.
[3] IQVIA, "Pharmaceutical Market Trends," 2023.
[4] Novartis Annual Reports, "Patent Expiry and Market Share," 2012.